Trial · NCT01864525
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
NCT01864525, Phase 1, Phase 2, Completed, Syracuse University; results first posted 2018-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Octanoic Acid for Treatment of Essential Voice Tremor. Trials, record NCT01864525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01864525
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Octanoic Acid for Treatment of Essential Voice Tremor
- NCT number
- NCT01864525
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Syracuse University
- Conditions
- Essential Voice Tremor, Vocal Tremor, Voice Tremor, Essential Tremor of Voice
- Interventions
- Octanoic acid, Inactive capsule
- First posted
- 2013-05-29
- Last updated
- 2018-08-20
- Results first posted
- 2018-08-20
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2) | Voice recordings were used to measure the degree of tremor in the voice. Mean post-test values for each acoustic measure were compared after the octanoic acid and placebo conditions, with and without consideration of baseline values. Mean values represent the average of two testing days. Degree of amplitude tremor shows the extent of amplitude variation as a percent of the mean signal amplitude, with lower numbers indicating less amplitude tremor. Baseline values for magnitude of amplitude tremor across all participants and conditions ranged from 4.06 to 27.09, and post-test values ranged from 1.94 to 26.02. Degree of frequency tremor shows the extent of fundamental frequency variation as a percent of the mean signal frequency, with lower numbers indicating less frequency tremor. Baseline values for magnitude of frequency tremor across all participants and conditions ranged from 1.21 to 15.31, and post-test values ranged from 0.60 to 13.86. |
| Secondary | Auditory-perceptual Tremor Severity Ratings | Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2). | Three experienced listeners independently rated each participant's voice from paired sample recordings comparing the baseline to post-test samples in randomized order for each condition. Sustained vowel and sentence-level recordings were rated, with decoded samples later analyzed for 1=better for post-test compared to baseline, 0= no difference between post-test and baseline. Maximum score for each participant was 3 (post-test was better for each of three raters). The range of possible scores was the sum of each of three raters' scores (0 to 3), with 0 indicating no difference between baseline and post-test voice tremor severity rating, and 3 indicating better voice (less tremor severity) at post-testing compared to pre-testing. Mean post-test values for task were compared for the octanoic acid and placebo conditions, and all raters were blind to which sample was a baseline versus a post-test recording, and which samples were associated with the \[placebo or octanoic acid conditions. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2) | percentage of voice signal with tremor | MEAN | |
| SECONDARY | Auditory-perceptual Tremor Severity Ratings | Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2). | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Placebo | Baseline Magnitude of Acoustic Amplitude Tremor | 12.91 | Standard Deviation 6.46 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Octanoic Acid | Baseline Magnitude of Acoustic Amplitude Tremor | 13.49 | Standard Deviation 6.48 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Placebo | Post-test Magnitude of Acoustic Amplitude Tremor | 12.43 | Standard Deviation 7.37 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Octanoic Acid | Post-test Magnitude of Acoustic Amplitude Tremor | 9.35 | Standard Deviation 5.42 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Placebo | Baseline Magnitude of Acoustic Frequency Tremor | 5.57 | Standard Deviation 4.29 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Octanoic Acid | Baseline Magnitude of Acoustic Frequency Tremor | 5.19 | Standard Deviation 3.58 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Placebo | Post-test Magnitude of Acoustic Frequency Tremor | 5.35 | Standard Deviation 3.76 | percentage of voice signal with tremor |
| Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor | Octanoic Acid | Post-test Magnitude of Acoustic Frequency Tremor | 3.98 | Standard Deviation 2.94 | percentage of voice signal with tremor |
| Auditory-perceptual Tremor Severity Ratings | Placebo | Sustained vowel, summed binary ratings (0-3) | 1.25 | Standard Deviation 1.13 | units on a scale |
| Auditory-perceptual Tremor Severity Ratings | Octanoic Acid | Sustained vowel, summed binary ratings (0-3) | 1.53 | Standard Deviation 1.13 | units on a scale |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Inactive Capsule First | 10 | |
| Overall Study | STARTED | Octanoic Acid First | 7 | |
| Overall Study | COMPLETED | Inactive Capsule First | 9 | |
| Overall Study | COMPLETED | Octanoic Acid First | 7 | |
| Overall Study | NOT COMPLETED | Inactive Capsule First | 1 | |
| Overall Study | NOT COMPLETED | Octanoic Acid First | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Placebo | 1 | 17 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Octanoic Acid | 0 | 17 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 17 |
| Total, all-cause mortality | Octanoic Acid | 0 | 17 |
| Total, other adverse events | Placebo | 1 | 17 |
| Total, other adverse events | Octanoic Acid | 0 | 17 |
| Total, serious adverse events | Placebo | 0 | 17 |
| Total, serious adverse events | Octanoic Acid | 0 | 17 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R03DC012429 | Effects of octanoic acid for treatment of essential voice tremor | LOWELL, SOREN YVETTE | SYRACUSE UNIVERSITY | NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS | 2013 to 2015 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Octanoic Acid vs Placebo: deaths from any cause | Trial comparisons |
| Octanoic Acid vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01864525
GET https://conductscience.org/api/trials/v1/NCT01864525/registered